ChemoCentryx Inc (NASDAQ: CCXI) is screaming for the top in the market this morning, and for good reason. The company announced that it has received approval from the United States Food and Drug Administration for TAVNEOS. Here’s the scoop:
This article originally appeared at CNA Finance.